Institute of Neuroscience and Medicine (INM-3, INM-4) Forschungszentrum Jülich, Jülich.
Department of Nuclear Medicine, RWTH Aachen University Clinic, Aachen.
Curr Opin Neurol. 2018 Aug;31(4):354-361. doi: 10.1097/WCO.0000000000000574.
The aim of this study was to give an update on the emerging role of PET using radiolabelled amino acids in the diagnostic workup and management of patients with cerebral gliomas and brain metastases.
Numerous studies have demonstrated the potential of PET using radiolabelled amino acids for differential diagnosis of brain tumours, delineation of tumour extent for treatment planning and biopsy guidance, differentiation between tumour progression and recurrence versus treatment-related changes, and for monitoring of therapy. The Response Assessment in Neuro-Oncology (RANO) working group - an international effort to develop new standardized response criteria for clinical trials in brain tumours - has recently recommended the use of amino acid PET imaging for brain tumour management in addition to MRI at every stage of disease. With the introduction of F-18 labelled amino acids, a broader clinical application has become possible, but is still hampered by the lack of regulatory approval and of reimbursement in many countries.
PET using radiolabelled amino acids is a rapidly evolving method that can significantly enhance the diagnostic value of MRI in brain tumours. Current developments suggest that this imaging technique will become an indispensable tool in neuro-oncological centres in the near future.
本研究旨在介绍放射性标记氨基酸 PET 在脑胶质瘤和脑转移瘤患者诊断和治疗管理中的新作用。
大量研究表明，放射性标记氨基酸 PET 对脑肿瘤的鉴别诊断、治疗计划和活检指导的肿瘤范围划定、肿瘤进展与复发与治疗相关变化的鉴别、以及治疗监测具有潜在价值。神经肿瘤学反应评估（RANO）工作组——一个为脑肿瘤临床试验制定新的标准化反应标准的国际努力——最近建议在疾病的每个阶段，除了 MRI 外，还使用氨基酸 PET 成像进行脑肿瘤管理。随着 F-18 标记氨基酸的引入，更广泛的临床应用成为可能，但在许多国家，由于缺乏监管批准和报销，这种成像技术仍然受到阻碍。
放射性标记氨基酸 PET 是一种快速发展的方法，可以显著提高 MRI 在脑肿瘤中的诊断价值。目前的发展表明，这种成像技术将在不久的将来成为神经肿瘤学中心不可或缺的工具。
